Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

GSK has claimed its second breakthrough designation ... extensive-stage SCLC. Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...

Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.86% to 8,280.36.

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025 ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...